Med. praxi. 2025;22(1):59-64 | DOI: 10.36290/med.2024.055

Prevention of cardiovascular diseases by reducing blood pressure variability with a fixed combination of antihypertensive drugs, case studies

MUDr. Ivan Řiháček, Ph.D.
Ordinace Řiháčkovi, s. r. o., Brno

Hypertension is the most important risk factor for cardiovascular diseases. Increased blood pressure variability worsens cardiovascular risk. Long-acting calcium channel blockers and thiazide or thiazide-like diuretics reduce blood pressure variability. Target blood pressure values in the new recommendations are 120-129/70-79 mmHg. To achieve them, we use in the first step a fixed combination of long-acting calcium channel blockers or diuretics with renin-angiotensin blockers. In the second step a fixed triple combination of all three drugs.

Keywords: hypertension, blood pressure variability, blood pressure targets, cardiovascular disease, fixed combination of antihypertensive drugs.

Received: December 12, 2024; Accepted: December 20, 2024; Published: February 20, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Řiháček I. Prevention of cardiovascular diseases by reducing blood pressure variability with a fixed combination of antihypertensive drugs, case studies. Med. praxi. 2025;22(1):59-64. doi: 10.36290/med.2024.055.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R, Bruthans J, Wohlfahrt P, et al. 30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post­‑MONICA, 1985 - 2016/17. PLoS One. 2020 May 11;15(5):e0232845. doi: 10.1371/journal.pone.0232845. PMID: 32392239; PMCID: PMC7213700. Go to original source... Go to PubMed...
    2. Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new­‑onset type 2 diabetes: an individual participant data meta­‑analysis. Lancet. 2021;398:1803-10. Go to original source... Go to PubMed...
    3. Watson S, Gupta A, Poulter NR. Visit­‑to­‑visit variability of systolic blood pressure in hypertensive patients treated exlusively with a combination treatment in the Anglo Scandinvaian Cardiac Outcomes Trial­‑BPLA. J Hypertens. 2014;32(e­‑suppl 1):e125.9C.06.
    4. Gupta A, Whiteley WN, Godec T. Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial. European Heart Journal. 2024;45:1159-1169. Go to original source... Go to PubMed...
    5. Palatini P, Saladini F, Mos L, et al. Short­‑term blood pressure variability outweighs average 24-h blood pressure in the prediction of cardiovascular events in hypertension of the young. J Hypertens. 2019;Jul 37(7):1419-1426. Go to original source... Go to PubMed...
    6. Mena LJ, Maestre GE, Hansen TW, et al. How many measurements are needed to estimate blood pressure variability without loss of prognostic information? Am J Hypertens. 2014 Jan;27(1):46-55. doi: 10.1093/ajh/hpt142. Go to original source... Go to PubMed...
    7. Verdecchia P, Borgioni C, Ciucci A, et al. Prognostic significance of blood pressure variability in essential hypertension. Blood pressure Monitoring. 1996;1:3-11. Go to original source...
    8. Bilo JA, Grzegorza BC, Giglio A, et al. New method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall. J Hypertens. 2007;25(10):2058-2066. doi: 10.1097/HJH.0b013e32829c6a60. Go to original source... Go to PubMed...
    9. Bilo G, Dolan E, O'Brien E, et al. The impact of systolic and diastolic blood pressure variability on mortality is age dependent: Data from the Dublin Outcome Study. Eur J Prev Cardiol. 2020;27:355-364. Go to original source... Go to PubMed...
    10. Kikuya M, Ohkubo T, Metoki H, et al. Day­‑by­‑day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension. 2008;52:1045-1050. Go to original source... Go to PubMed...
    11. Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on­‑treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37:955-964. Go to original source... Go to PubMed...
    12. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo­‑Scandinavian Cardiac Outcomes Trial­‑Blood Pressure Lowering Arm (ASCOT­‑BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906. Go to original source... Go to PubMed...
    13. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit­‑to­‑visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375: 895-905. Go to original source... Go to PubMed...
    14. Rothwell PM. Review. Limitations of the usual blood­‑pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938-48. Go to original source... Go to PubMed...
    15. Webb AJS, Fischer U, Mehta Z et al. Effects of antihypertensive­‑drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta­‑analysis. Lancet. 2010;375:906-15. Go to original source... Go to PubMed...
    16. Filipovský Jan. Variabilita krevního tlaku u hypertenze. Hypertenze a kardiovaskulární prevence. 2024;2:33-38.
    17. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874-2071. Go to original source... Go to PubMed...
    18. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal 2024;45:3912-4018. https://doi.org/10.1093/eurheartj/ehae178. Go to original source... Go to PubMed...
    19. Widimský J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze Doporučení České společnosti pro hypertenzi 2022. Hypertenze a kardiovaskulární prevence. 2022;12(2):suppl:1-25.
    20. Karen I, Widimský J, Cífková R, et al. Arteriální hypertenze - novelizace 2024. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Společnost všeobecného lékařství ČLS JEP (www.svl.cz). Centrum doporučených postupů pro praktické lékaře, Sokolská 490/31, 120 00 Praha 2. Třetí, aktualizované vydání, Praha 2024;3-31. ISBN 978-80-88280-63-7.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.